Clinical Trials Browser

Turcot syndrome, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02158858 2025-10-08

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1/2 Completed

336 enrolled

MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04562389 2025-10-03

SENTRY

Phase 3 Active not recruiting

353 enrolled

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated

177 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06397313 2025-09-23

POTAMI-61

Phase 2 Recruiting

230 enrolled

Myeloid

Neoplasm Metastasis, Primary Myelofibrosis

NCT05223920 2025-09-22

MK-3543-005

Phase 2 Completed

81 enrolled 13 charts

Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

NCT04817007 2025-09-10

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

Phase 1/2 Active not recruiting

216 enrolled

Myeloid

Primary Myelofibrosis

NCT04629508 2025-09-02

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase 2 Completed

4 enrolled 10 charts

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

NCT03952039 2025-08-28

FREEDOM2

Phase 3 Completed

202 enrolled 23 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06378437 2025-08-19

A Study of GLB-001 in Patients With Myeloid Malignancies

Phase 1 Recruiting

108 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Phase 3 Recruiting

150 enrolled

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Active not recruiting

21 enrolled

Myeloid

Neoplasms, Primary Myelofibrosis

NCT04717414 2025-07-10

INDEPENDENCE

Phase 3 Active not recruiting

313 enrolled

Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01688011 2025-07-03

Connect® Myeloid Disease Registry

Terminated

2,013 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Phase 2 Active not recruiting

90 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05423691 2025-04-13

TREG108

Phase 1 Recruiting

24 enrolled

Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Thrombocytosis, Bone Marrow Neoplasms, Primary Myelofibrosis

Clinical Trials

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

CINC424A2X01B Rollover Protocol

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

KEAP

LIMBER

MK-3543-017

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Managed Access Programs for INC424, Ruxolitinib

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

SENTRY

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

POTAMI-61

MK-3543-005

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

FREEDOM2

A Study of GLB-001 in Patients With Myeloid Malignancies

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

INDEPENDENCE

Connect® Myeloid Disease Registry

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

TREG108